StrongDecrease
BMI
Dulaglutide → BMI
Dulaglutide → BMI
Evidence profile
StrongDecreaseWeight & Anthropometrics
Unlock full evidence details
Research Summary
Analyzed using Evidence Intelligence™
Dulaglutide may improve weight loss in obese patients with diabetes
Key finding
The patient achieved a weight loss of 40 kg (−21%) over 6 months.
This study evaluated the effects of Dulaglutide on weight loss in a morbidly obese patient with type 2 diabetes, resulting in significant weight reduction and improved glycemic control.
Evidence strength
Moderate confidence
Study type
Non-randomized CT
Follow-up
Medium-Term (3–12 mo)
Some Concerns bias
Last updated July 4, 2026Quick read
Study at a glance
The essential study design details in one scan.
Population
Young Adult (19–39), Middle Aged (40-64), Male, Female, Asia-Pacific (APAC), with T2 Diabetes
Intervention
Dulaglutide
Study type
Non-randomized CT
Follow-up
Medium-Term (3–12 mo)
Primary outcome
Weight loss
Evidence
Moderate confidence
Plain-language summary
What this paper says
A plain-language read of the study's main message and where it applies.
Study focus
This study evaluated the effects of Dulaglutide on weight loss in a morbidly obese patient with type 2 diabetes, resulting in significant weight reduction and improved glycemic control.
Clinical relevance
This study highlights the potential of Dulaglutide as a therapeutic option for weight management in patients with type 2 diabetes, addressing a critical aspect of diabetes care. Effective weight loss can lead to improved health outcomes and reduced complications associated with obesity and diabetes.
Keep in mind
Single participant limits generalizability. Non-randomized design may introduce bias. No long-term follow-up data available.
Published in
Journal Reference
Publication details and source links for this paper.
Sohail B, Sahil B, Grishma S, et al. Dulaglutide for Weight Loss in a Morbidly Obese Patient with Type 2 Diabetes. Clinical Case Reports. 2024;12(9):e9403. doi:10.1002/ccr3.9403
Save this study and add notes to your research library.
Main Effects
Weight loss of 40 kg (−21%) over 6 months.
BMI decreased by 10.3 kg/m² over 6 months.
Daily caloric intake reduced from 6924 to 2538.9 calories.
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Dulaglutide and BMI, Body weight, Caloric intake, and 2 more.
This study contributes evidence to
Primary intervention
Dulaglutide
Primary outcomes
- BMI
- Body weight
- Caloric intake
Evidence topics
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
5
Evidence pairs
5
Relationships
2
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 64
2
Related topics
5
Evidence pairs
130
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 5 evidence relationships
- Includes primary outcome data
- Linked to 2 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Core evidence
Study findings
The primary outcomes reported in this study.
StrongDecrease
Body weight
Dulaglutide → Body weight
Dulaglutide → Body weight
Evidence profile
StrongDecreaseWeight & Anthropometrics
Unlock full evidence details
StrongDecrease
Caloric intake
Dulaglutide → Caloric intake
Dulaglutide → Caloric intake
Evidence profile
StrongDecreaseMetabolic Health
Unlock full evidence details
NoneNo Change
Gastrointestinal disorders incidence
Dulaglutide → Gastrointestinal disorders incidence
Dulaglutide → Gastrointestinal disorders incidence
Evidence profile
NoneNo ChangeSafety
Unlock full evidence details
NoneNo Change
Time to glycemic target
Dulaglutide → Time to glycemic target
Dulaglutide → Time to glycemic target
Evidence profile
NoneNo ChangeGlycemic Control
Unlock full evidence details
Unlock full evidence analysis
Create a free account to access effectiveness ratings, evidence strength and depth scores, consistency analysis, and direct links to all supporting studies.
Evidence Suggest
- 40 kg weight loss observed in 6 months.
- 10.3 kg/m² reduction in BMI recorded.
- Daily caloric intake decreased by 4385.1 calories.
Who this applies to
- Morbidly obese adults with type 2 diabetes.
- Patients seeking pharmacological weight loss options.
Keep in Mind
- Results are based on a single case study.
- Further research needed to confirm findings.
- Effectiveness in broader populations remains unclear.
Between the Lines
- Single participant limits generalizability.
- Non-randomized design may introduce bias.
- No long-term follow-up data available.
Unlock Full Analysis
Create a free account to unlock the bias score, detailed effectiveness analysis, and clinical outcomes for this study.
Already have an account?
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and Body Weight, GLP-1 Receptor Agonists and Body Mass Index.
Related evidence relationships
Explore in Evidence ArchiveThis study contributes to the evidence on the following intervention-outcome relationships.
Included in these evidence collections
Curated evidence collections and hubs this study is part of.
Body Mass Index Evidence Hub
All studies measuring Body Mass Index
3 studies
outcome_hubMeasures Body Mass Index as a key outcome.
Body Weight Evidence Hub
All studies measuring Body Weight
2 studies
outcome_hubMeasures Body Weight as a key outcome.
GLP-1 Receptor Agonists Evidence Hub
All studies on GLP-1 Receptor Agonists
2 studies
intervention_hubContributes to GLP-1 Receptor Agonists evidence base.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explore more in the evidence archive
Jump to pre-filtered views in the evidence archive.
All studies on Dulaglutide and Body weight
Intervention: DulaglutideOutcome: Body weight
2 results
All studies on Dulaglutide and BMI
Intervention: DulaglutideOutcome: BMI
3 results
All studies on Dulaglutide
Intervention: Dulaglutide
2 results
All studies measuring Body weight
Outcome: Body weight
2 results
All studies measuring BMI
Outcome: BMI
3 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does GLP-1 Receptor Agonists affect body weight?
Emerging Evidence
GLP-1 Receptor Agonists may improve Body Weight.
ConsensusScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Body weight
EvidenceScore™ Emerging | EvidenceScore™ 49.3 | moderate positive | ConsensusScore™ Consistent | 1 study
Why this answer: This answer is based on 23 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does GLP-1 Receptor Agonists affect body mass index?
Emerging Evidence
GLP-1 Receptor Agonists may improve Body Mass Index.
ConsensusScore™: Results are consistent across studies.
Ranked evidence signals
- 1
BMI
EvidenceScore™ Emerging | EvidenceScore™ 48.5 | weak positive | ConsensusScore™ Consistent | 1 study
Why this answer: This answer is based on 9 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does GLP-1 Receptor Agonists affect gastrointestinal adverse events?
Limited Evidence
Current evidence does not show a clear benefit of GLP-1 Receptor Agonists for Gastrointestinal Adverse Events.
ConsensusScore™: Results are mixed and should be interpreted cautiously.
Evidence caveat: The available evidence reports mixed findings.
Ranked evidence signals
- 1
Gastrointestinal disorders incidence
EvidenceScore™ Limited | EvidenceScore™ 34.1 | neutral | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is cautious because the available studies report mixed findings.
Limitations
- Population details are unavailable.
Does GLP-1 Receptor Agonists improve cgm time in range?
Limited Evidence
Current evidence does not show a clear benefit of GLP-1 Receptor Agonists for CGM Time in Range.
ConsensusScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Time to glycemic target
EvidenceScore™ Limited | EvidenceScore™ 32.9 | neutral | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on 3 supporting studies and existing graph evidence signals.
Limitations
- Consistency cannot yet be determined.
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, archive views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in archive
Open broader archive views for this relationship.
Related research
Read related research summaries.
Newer diabetes drugs show stronger weight and blood sugar benefits in prediabetesGLP-1 agonists reduce heart fat thickness in diabetes.Higher dulaglutide doses improve weight loss in type 2 diabetesDietary supplements may lower diabetes risk in prediabetesDigital intervention improves glycemic control in type 2 diabetes patients
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.